Acceleron Pharma Inc. (XLRN) Stock Rating Reaffirmed by Instinet

Instinet reissued their buy rating on shares of Acceleron Pharma Inc. (NASDAQ:XLRN) in a report published on Wednesday morning. Instinet currently has a $58.00 price objective on the biopharmaceutical company’s stock.

Several other research analysts have also weighed in on XLRN. Cann reissued a hold rating on shares of Acceleron Pharma in a research report on Tuesday, June 13th. Oppenheimer Holdings, Inc. reissued a market perform rating on shares of Acceleron Pharma in a research report on Tuesday, June 13th. CIBC lowered Acceleron Pharma from an outperform rating to a market perform rating in a research report on Tuesday, June 13th. FBR & Co set a $63.00 price target on Acceleron Pharma and gave the company a buy rating in a research report on Tuesday, June 13th. Finally, Morgan Stanley dropped their price target on Acceleron Pharma from $51.00 to $42.00 and set an overweight rating on the stock in a research report on Tuesday, June 13th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company. Acceleron Pharma currently has a consensus rating of Hold and a consensus target price of $42.23.

Acceleron Pharma (NASDAQ XLRN) opened at 30.31 on Wednesday. Acceleron Pharma has a 12 month low of $23.07 and a 12 month high of $41.69. The stock’s market cap is $1.17 billion. The stock has a 50 day moving average price of $28.63 and a 200-day moving average price of $27.64.

Acceleron Pharma (NASDAQ:XLRN) last announced its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by $0.08. The company had revenue of $3.71 million for the quarter, compared to analyst estimates of $3.38 million. Acceleron Pharma had a negative return on equity of 38.57% and a negative net margin of 659.04%. The firm’s revenue for the quarter was down 79.6% on a year-over-year basis. During the same period last year, the firm earned $0.13 earnings per share. On average, analysts expect that Acceleron Pharma will post ($2.54) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/2654160/acceleron-pharma-inc-xlrn-stock-rating-reaffirmed-by-instinet.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Bessemer Group Inc. raised its position in shares of Acceleron Pharma by 3,999.1% in the fourth quarter. Bessemer Group Inc. now owns 4,755 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 4,639 shares during the last quarter. Tudor Investment Corp Et Al raised its position in shares of Acceleron Pharma by 24.1% in the fourth quarter. Tudor Investment Corp Et Al now owns 8,389 shares of the biopharmaceutical company’s stock valued at $214,000 after buying an additional 1,631 shares during the last quarter. Bank of Montreal Can purchased a new position in shares of Acceleron Pharma during the first quarter valued at $237,000. Parametric Portfolio Associates LLC purchased a new position in shares of Acceleron Pharma during the first quarter valued at $241,000. Finally, Tudor Investment Corp ET AL raised its position in shares of Acceleron Pharma by 8.5% in the first quarter. Tudor Investment Corp ET AL now owns 9,105 shares of the biopharmaceutical company’s stock valued at $241,000 after buying an additional 716 shares during the last quarter. 83.56% of the stock is currently owned by institutional investors.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.